8-K: Humana Reports Strong Q2 2026 Results, Affirms Guidance

Humana Inc. announced solid second quarter 2026 financial results, reporting $7.61 in Adjusted EPS and reaffirming its full-year Adjusted EPS guidance of at least $9.00.

Summary

• Humana Inc. reported strong financial results for the second quarter of 2026 (2Q26), with Adjusted EPS of $7.61, aligning with expectations.
• The company affirmed its full-year 2026 Adjusted EPS guidance of at least $9.00.
• The Insurance segment reported a GAAP benefit ratio of 91.2%, in line with expectations.
• CenterWell segment patient count grew by 27% year-to-date, reaching approximately 622,000 patients.
• Humana was awarded a statewide Illinois Medicaid managed care contract, expected to commence in January 2027.
• The company is strategically expanding its CenterWell and Medicaid footprints.
• A virtual investor update is scheduled for December 10th, 2026, to review progress against long-term earnings growth commitments.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong operational execution in the current quarter and affirmation of full-year adjusted guidance, despite a downward revision in GAAP EPS guidance and acknowledgment of headwinds.

Positives

• Second quarter 2026 Adjusted EPS of $7.61 met high-end guidance expectations.
• Full-year 2026 Adjusted EPS guidance of at least $9.00 was affirmed.
• Insurance segment benefit ratio of 91.2% was in line with management's guidance.
• CenterWell Senior Primary Care patient growth was 27% year-to-date, reaching 622,000 patients.
• Awarded a statewide Illinois Medicaid managed care contract for January 2027.
• Florida Medicaid contract extended for an additional 4 years.
• Strong retention rate and Net Promoter Score (NPS) in the Primary Care business.
• Capital efficiency efforts are delivering results, with a debt-to-capitalization ratio of 42.7%.

Negatives

• GAAP EPS guidance for FY 2026 was revised downwards to 'at least $6.52' from 'at least $8.36'.
• The company anticipates a year-over-year decline in FY 2026 Adjusted EPS due to the Star Ratings headwind for Bonus Year (BY) 2026.
• Third quarter Adjusted EPS is expected to be approximately negative 10% of full-year Adjusted EPS.
• Third quarter Insurance segment benefit ratio is expected to be slightly above 94%.
• Navigating procurement challenges related to recent awards in Texas and Georgia.
• The company is still evaluating a pipeline of initiatives to further strengthen the balance sheet.

Risks

• Potential for inadequate premiums to cover healthcare service costs.
• Inability to implement clinical initiatives to improve member experience and lower costs.
• Inadequate estimates of benefits expense.
• Failure to effectively implement operational and strategic initiatives, including Medicare and CenterWell growth.
• Decline in Medicare Advantage Star Ratings impacting quality bonus payments and revenues.
• Risks associated with data integrity, information systems, and cybersecurity attacks.
• Involvement in various legal actions, governmental investigations, and routine internal reviews.
• Changes to the risk-adjustment model utilized by CMS could materially affect operating results.

Future Outlook

The company affirmed its full-year 2026 Adjusted EPS guidance of at least $9.00, anticipating a year-over-year decline due to the Star Ratings headwind. Guidance for FY 2026 GAAP EPS was revised to at least $6.52. The company expects its approach to 2027 individual MA bids to drive progress towards a sustainable pre-tax margin of at least 3% by 2028 and is positioned to unlock the business's earnings potential by 2028.

Management Comments

• "The first half of the year went well, and we're right where we said we'd be at Investor Day last year," said Humana President and CEO Jim Rechtin.
• "When we get the clinical care right and run the business more efficiently, everything else follows—stronger earnings and better health and experiences for the people we serve."
• "We expect that our approach to 2027 individual MA bids will drive meaningful progress against our commitment of returning to a sustainable pre-tax margin of at least 3% in 2028."
• "We believe we are well positioned to deliver on our commitment of unlocking the earnings potential of the business by 2028 as laid out at our 2025 Investor Day, supported by our expanded membership base, relentless focus on returning to Top Quartile Stars results, and continued discipline across pricing, clinical excellence, operating efficiencies and capital allocation."

Industry Context

StockSavvy.ai notes that Humana's results reflect ongoing trends in the health insurance sector, particularly the increasing importance of Medicare Advantage and the strategic expansion into primary care services through its CenterWell division. The company's focus on Star Ratings and value-based care aligns with broader industry shifts towards quality outcomes and cost efficiency.

Comparison to Industry Standards

• Humana's Adjusted EPS of $7.61 for 2Q26 is at the high end of its guidance, indicating strong operational execution compared to internal expectations.
• The Insurance segment benefit ratio of 91.2% is in line with management's guidance of 'slightly above 91 percent', suggesting effective cost management relative to revenue.
• CenterWell's patient growth of 27% year-to-date in Senior Primary Care outpaces general healthcare market growth, indicating successful strategic expansion.
• The company's affirmed full-year Adjusted EPS guidance of at least $9.00, despite a revised GAAP EPS outlook, suggests confidence in managing non-GAAP adjustments and operational performance.
• The decline in GAAP EPS guidance from $8.36 to $6.52 highlights the impact of specific accounting adjustments or headwinds not captured in Adjusted EPS, a common challenge in the healthcare sector.

Legal Proceedings

• Humana filed a lawsuit seeking to set aside and vacate the 2025 Star Ratings of its Medicare Advantage plans, which was rejected by the Court on October 14, 2025; the company has appealed this decision.
• Humana is involved in various legal actions, including provider contract disputes and qui tam litigation.
• Navigating procurement challenges related to recent awards in Texas and Georgia.

Stakeholder Impact

• Shareholders: Affirmation of Adjusted EPS guidance and strategic growth initiatives are positive indicators for future value.
• Members: Continued expansion of Medicare Advantage and Medicaid, along with growth in CenterWell services, aims to improve health outcomes and care delivery.
• Employees: Focus on operational efficiencies and transformation initiatives may impact workforce dynamics.
• Providers: Increased engagement through value-based care models and expansion of primary care services.

Next Steps

• Hold a virtual investor update on December 10th, 2026, to provide a mark to market against the framework laid out at the 2025 Investor Day.
• Continue strategic expansion of CenterWell and Medicaid platforms.
• Focus on achieving Top Quartile Stars results in Bonus Year (BY) 2028.
• Pursue non-core asset divestitures, such as the minority interest in Gentiva.
• Maintain debt to capitalization ratio near the long-term target of approximately 40%.

Key Dates

Recommendation

The company demonstrates solid operational execution and affirms its adjusted guidance, with positive growth in key segments like CenterWell and Medicare Advantage. However, the downward revision in GAAP EPS guidance and ongoing headwinds related to Star Ratings and regulatory changes warrant a cautious 'hold' stance until further clarity on long-term margin recovery and risk mitigation strategies is provided.

Keywords

Humana, Medicare Advantage, CenterWell, Health Insurance, Healthcare Services, Medicaid, EPS, Financial Results